Priothera
Dublin
About Priothera
Priothera is a clinical-stage company developing orally applied sphingosine 1 phosphate (S1P) receptor modulators for haematological malignancies. We are dedicated to improving the lives of patients suffering from hematological malignancies by delivering an innovative immune modulator to enhance the curative potential of allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in these patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $58.8M
- Funding stage: Early Stage Venture
- Last round: Grant (Jun 2025)
- Website: priothera.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/priothera-29153 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.